FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
10/31/2023
Back to search
Official data from USPTO
CHEMOMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
10/31/2023
Trademark type
Word
Nice classes
5, 42
Filing date
01/09/2022
Registration date
07/11/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/11/2023
Last transaction
07/11/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
78
Owner location
Tel Aviv - Yafo, IL
Examiner
BURCH,JILLIAN RENEE
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Chemomab Therapeutics Ltd.
Representatives
Jacqueline Zion Pearl Cohen Zedek Latzer Baratz LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medicinal products for the treatment of inflammatoryfibroticautoimmune diseases
Class 42
Providing medical research informationbiologicalchemicalpharmaceuticalclinical data in the field of diagnosticprophylactic and therapeutic properties of pharmaceuticals for treatment of fibrotic diseasesautoimmune diseasesinflammatory diseases; research and development of pharmaceuticals for the treatment of fibrotic diseasesinflammatory diseasesautoimmune diseases
Publications
History of USPTO decisions and trademark events.
25 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/12/2023
FIMP
FINAL DISPOSITION PROCESSED
10/12/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/11/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
07/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/25/2023
PUBO
PUBLISHED FOR OPPOSITION
04/25/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/24/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/05/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/17/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/16/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/15/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/15/2023
RFNT
REFUSAL PROCESSED BY IB
02/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/13/2023
RFRR
REFUSAL PROCESSED BY MPU
01/13/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/03/2022
CNRT
NON-FINAL ACTION WRITTEN
11/02/2022
DOCK
ASSIGNED TO EXAMINER
10/17/2022
MAFR
APPLICATION FILING RECEIPT MAILED
03/11/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/07/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/03/2022
Continuous trademark protection
Get notified about every new filing that threatens CHEMOMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.